Aoxing Pharmaceutical (AXN) Breathtaking Numbers; Enzo Biochem (ENZ) Profitable Core Business


Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) stock finished Monday’s market activity at $1.55

Shares of Aoxing Pharmaceutical soared more than 15% in pre-market trading Tuesday after it delivered its first profitable year with an impressive growth performance in revenue and profit.

For its fiscal year 2015, Aoxing Pharmaceutical posted revenue of $25.5 million, a 100% increase year over year, and net income of $5.8 million, or $0.09 per share, compared to a net loss of ($8.6) million, or $(.16) per share in the same period the prior year.

Aoxing Pharmaceutical Company, a US incorporated specialty pharmaceutical company with its operations in China, has 72.17M Shares Outstanding, Market Capitalization (intraday) of $112.59M and AXN stock 52-week range is between $0.19 and $3.48 per share



Shares of Enzo Biochem Inc. (NYSE:ENZ) closed at $3.73 on Monday’s trading session.

For its fourth quarter fiscal 2015, Enzo Biochem posted revenues of $25.7 million, a 3% increase year over year, and GAAP net income of $8.4 million (including legal settlements of $11.3 million), or $0.18 per diluted share, compared to net loss of ($3.2) million, or ($0.07) per share in the same quarter the prior year, representing one of the company’s best quarters in several years.

Enzo Biochem said on Tuesday that Affymetrix, Inc. (Nasdaq:AFFX) will make a payment of $10 million to the company as part of a patent infringement settlement

Enzo Biochem, a pioneer in molecular diagnostics, has 46.06M Shares Outstanding, Market Capitalization (intraday) of $171.80M and ENZ stock 52-week range is $2.26 – $5.38 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at